Duality Biotherapeutics Inc. (4ZB)

Overview

Duality Biotherapeutics Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China. Established in 2020, the company is at the forefront of developing next-generation antibody-drug conjugate (ADC) therapeutics. These cutting-edge treatments are engineered to specifically target and deliver cytotoxic agents to cancer cells, enhancing precision and efficacy in oncology. Duality Biotherapeutics operates both domestically and internationally, with its primary revenue base situated in China. Through a combination of strategic collaborations and robust in-house research and development (R&D), the company seeks to address significant unmet clinical needs in cancer care and play a vital role in the advancing landscape of targeted cancer therapies.

Products and Services

• DB-1303

  DB-1303 is an advanced ADC candidate targeting the HER2 protein, which is overexpressed in certain breast and gastric cancers. This innovative therapeutic aims to deliver cytotoxic agents directly to cancer cells expressing HER2, thereby improving the effectiveness of treatment while minimizing damage to healthy tissues.

• DB-1311

  Partnered with BioNTech, DB-1311 targets the B7-H3 protein, which plays a significant role in tumor immunity and is expressed in various malignancies. By utilizing this ADC, the company aims to enhance anti-tumor responses and develop more effective treatments for cancer patients with B7-H3 expressing tumors.

• TROP2-targeted candidates

  Duality Biotherapeutics is also developing candidates that target Trop2, a cell surface protein involved in tumor growth and progression. These therapeutics are designed to utilize cytotoxic agents, potentially leading to improved therapeutic outcomes in cancers where Trop2 is prevalent.

• HER3-targeted candidates

  Another focus area for Duality Biotherapeutics is the development of therapies targeting HER3. This protein is implicated in the resistance mechanisms of several cancers, and targeting it may overcome therapeutic resistance and improve the efficacy of existing treatments.

• Bispecific platforms

  The company is exploring innovative bispecific platforms that can bind two different targets, thereby creating a dual-action therapeutic strategy. This approach may enhance the effectiveness of cancer treatment by simultaneously attacking multiple pathways involved in tumor growth and survival.